Innovation in Action: CEVR at ASGH 2026

The InnoHK Centre for Eye and Vision Research (CEVR) is proud to have showcased our groundbreaking research and spin-off innovations at the 2026 Asia Summit on Global Health (ASGH). 

Spotlight: Viromids
We were thrilled to present Viromids, a reusable, low-cost gene-delivery platform, inspired by a nonpathogenic virus that naturally inhabits more than 95% of humans, creating a versatile and scalable, immune-silent delivery vector platform. Viromids carry the most tolerated and highest fidelity form of nucleic acid - circular single-stranded DNA (ssDNA) - produced entirely in E.coil, enabling the lowest-cost, and largest-scale fermentation and purification.

Commercial Innovation: Entoptica
Beyond our core research, CEVR’s spin-off company, Entoptica, demonstrated the Structured Light Observation Perception and Evaluation (SLOPE) device—a leap forward in age-related macular degeneration precision diagnostic technology.

Distinguished Guests
It was an honor to share our vision with esteemed leaders who are shaping the regional innovation landscape. We were privileged to welcome:

-Mr. Ivan Lee, JP (Commissioner for Innovation and Technology)
-Ms. Winnie Chan (Assistant Commissioner for Innovation and Technology)
-Prof. David Shum (Dean of the Faculty of Health and Social Sciences, PolyU)

As a flagship event co-organized by the HKSAR Government and the HKTDC, ASGH 2026 provided an unparalleled platform for global visibility and cross-border collaboration. CEVR remains steadfast in our commitment to bolstering Hong Kong’s evolution as a premier global hub for healthcare innovation.